Pseudotyping of lentiviral vector with novel vesiculovirus envelope glycoproteins derived from Chandipura and Piry viruses

Virology

Volumn 488, Issue , 2016, Pages 162-168

  Hu, Shuang ^a   Mohan Kumar, Dipu ^a   Sax, Chelsea ^a   Schuler, Clayton ^a   Akkina, Ramesh ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

Chandipura and Piry viral glycoproteins; Gene transduction with pseudotyped lentiviral vectors; Human serum resistant lentiviral vectors; Lentiviral vector pseudotyping

Indexed keywords

LENTIVIRUS VECTOR; VIRUS ENVELOPE PROTEIN; COMPLEMENT;

ARTICLE; BLOOD ANALYSIS; CHANDIPURA VIRUS; CONTROLLED STUDY; FREEZE THAWING; GENE TRANSFER; GENETIC TRANSDUCTION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; LYMPHOID PROGENITOR CELL; NONHUMAN; PIRY VIRUS; PRIORITY JOURNAL; PSEUDOTYPING; SENSITIVITY ANALYSIS; SEROLOGY; ULTRACENTRIFUGATION; VESICULOVIRUS; VIRAL TROPISM; VIRUS INACTIVATION; CELL CULTURE; CELL SURFACE DISPLAY; CHEMISTRY; GENETICS; IMMUNOLOGY; LENTIVIRINAE; PROCEDURES; STEM CELL; VIROLOGY;

CELL SURFACE DISPLAY TECHNIQUES; CELLS, CULTURED; COMPLEMENT SYSTEM PROTEINS; GENE TRANSFER TECHNIQUES; HUMANS; LENTIVIRUS; STEM CELLS; TRANSDUCTION, GENETIC; VESICULOVIRUS; VIRAL ENVELOPE PROTEINS; VIRUS INACTIVATION;

EID: 84948768459     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2015.11.012     Document Type: Article

References (36)

1. Akkina R.K., et al. High-efficiency gene transfer into CD34+ cells with a human immunodeficiency virus type 1-based retroviral vector pseudotyped with vesicular stomatitis virus envelope glycoprotein G. J. Virol. 1996, 70(4):2581-2585.
2. Anderson J., et al. Safety and efficacy of a lentiviral vector containing three anti-HIV genes-CCR5 ribozyme, tat-rev siRNA, and TAR decoy-in SCID-hu mouse-derived T cells. Mol. Ther. 2007, 15(6):1182-1188.
3. Baquero E., et al. Structure of the low pH conformation of Chandipura virus G reveals important features in the evolution of the vesiculovirus glycoprotein. PLoS Pathog. 2015, 11(3):e1004756.
4. Brun G., Bao X., Prevec L. The relationship of Piry virus to other vesiculoviruses: a re-evaluation based on the glycoprotein gene sequence. Intervirology 1995, 38(5):274-282.
5. Buchschacher G.L., Wong-Staal F. Development of lentiviral vectors for gene therapy for human diseases. Blood 2000, 95(8):2499-2504.
6. Burns J.C., et al. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc. Natl. Acad. Sci. USA 1993, 90(17):8033-8037.
7. Cartwright B., Brown F. Serological relationships between different strains of vesicular stomatis virus. J. Gen. Virol. 1972, 16(3):391-398.
8. Cicalese M.P., Aiuti A. Clinical applications of gene therapy for primary immunodeficiencies. Hum. Gene Ther. 2015, 26(4):210-219.
9. Cronin J., Zhang X.Y., Reiser J. Altering the tropism of lentiviral vectors through pseudotyping. Curr. Gene Ther. 2005, 5(4):387-398.
10. Dhanda V., Rodrigues F.M., Ghosh S.N. Isolation of Chandipura virus from sandflies in Aurangabad. Indian J. Med. Res. 1970, 58(2):179-180.
11. Emeagi P.U., et al. Lentiviral vectors: a versatile tool to fight cancer. Curr. Mol. Med. 2013, 13(4):602-625.
12. Frecha C., et al. Measles virus glycoprotein-pseudotyped lentiviral vector-mediated gene transfer into quiescent lymphocytes requires binding to both SLAM and CD46 entry receptors. J. Virol. 2011, 85(12):5975-5985.
13. Girard-Gagnepain A., et al. Baboon envelope pseudotyped LVs outperform VSV-G-LVs for gene transfer into early-cytokine-stimulated and resting HSCs. Blood 2014, 124(8):1221-1231.
14. Kang Y., et al. In vivo gene transfer using a nonprimate lentiviral vector pseudotyped with Ross River Virus glycoproteins. J. Virol. 2002, 76(18):9378-9388.
15. Kneissl S., et al. CD19 and CD20 targeted vectors induce minimal activation of resting B lymphocytes. PLoS One 2013, 8(11):e79047.
16. Kobinger G.P., et al. Filovirus-pseudotyped lentiviral vector can efficiently and stably transduce airway epithelia in vivo. Nat. Biotechnol. 2001, 19(3):225-230.
17. Li M.J., et al. Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. Mol. Ther. 2005, 12(5):900-909.
18. Lyles D.S., Kuzmin I.V., Rupprecht C.E. Rhabdoviridae. Fields Virology 2013, 2:885-922. Lippincott Williams & Wilkins, Philadelphia, PA. 6th ed.
19. Matrai J., Chuah M.K., VandenDriessche T. Recent advances in lentiviral vector development and applications. Mol. Ther. 2010, 18(3):477-490.
20. Mazarakis N.D., et al. Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery. Hum. Mol. Genet. 2001, 10(19):2109-2121.
21. Nagabhushan Kalburgi S., Khan N.N., Gray S.J. Recent gene therapy advancements for neurological diseases. Discov. Med. 2013, 15(81):111-119.
22. Naldini L., et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996, 272(5259):263-267.
23. Roth J.A., Cristiano R.J. Gene therapy for cancer: what have we done and where are we going?. J. Natl. Cancer Inst. 1997, 89(1):21-39.
24. Sakuma T., Barry M.A., Ikeda Y. Lentiviral vectors: basic to translational. Biochem. J. 2012, 443(3):603-618.
25. Salmon P., et al. High-level transgene expression in human hematopoietic progenitors and differentiated blood lineages after transduction with improved lentiviral vectors. Blood 2000, 96(10):3392-3398.
26. Sandrin V., et al. Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates. Blood 2002, 100(3):823-832.
27. Schauber C.A., et al. Lentiviral vectors pseudotyped with baculovirus gp64 efficiently transduce mouse cells in vivo and show tropism restriction against hematopoietic cell types in vitro. Gene Ther. 2004, 11(3):266-275.
28. Stitz J., et al. Lentiviral vectors pseudotyped with envelope glycoproteins derived from gibbon ape leukemia virus and murine leukemia virus 10A1. Virology 2000, 273(1):16-20.
29. Strang B.L., et al. Characterization of HIV-1 vectors with gammaretrovirus envelope glycoproteins produced from stable packaging cells. Gene Ther. 2004, 11(7):591-598.
30. Tesfay M.Z., et al. Vesiculovirus neutralization by natural IgM and complement. J. Virol. 2014, 88(11):6148-6157.
31. Trobridge G.D., et al. Cocal-pseudotyped lentiviral vectors resist inactivation by human serum and efficiently transduce primate hematopoietic repopulating cells. Mol. Ther. 2010, 18(4):725-733.
32. Wagemaker G. Lentiviral hematopoietic stem cell gene therapy in inherited metabolic disorders. Hum. Gene Ther. 2014, 25(10):862-865.
33. Witting S.R., Vallanda P., Gamble A.L. Characterization of a third generation lentiviral vector pseudotyped with Nipah virus envelope proteins for endothelial cell transduction. Gene Ther. 2013, 20(10):997-1005.
34. Yao Y., et al. Membrane fusion activity of vesicular stomatitis virus glycoprotein G is induced by low pH but not by heat or denaturant. Virology 2003, 310(2):319-332.
35. Zhou Q., Buchholz C.J. Cell type specific gene delivery by lentiviral vectors: new options in immunotherapy. Oncoimmunology 2013, 2(1):e22566.
36. Zhou Q., et al. Exclusive transduction of human CD4+ T Cells upon systemic delivery of CD4-targeted lentiviral vectors. J. Immunol. 2015, 195(5):2493-2501.